ArticleBMC complementary medicine and therapies2025
Evaluation of the in vivo antidiabetic, in vitro antioxidant and alpha amylase inhibitory effects of Ocimum lamiifolium Hochst ex Benth leaf hydromethanolic crude extract in streptozotocin-induced diabetic mouse model.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemical Profile and Bioactive Potential ofCurrent issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetes mellitus remains a global health issue, especially in rural areas of developing countries. Ocimum lamiifolium Hochst.ex Benth leaf has been tested for its short-term hypoglycemic effect in Kenya and is widely utilized for diabetes management in Ethiopia. However, its long-term effect have not been documented. This study aimed to examine the antidiabetic and antioxidant effects of the plant.
methodsIn this study, diabetes mellitus was induced in male Swiss albino mice using a single intra-peritoneal injection of 150 mg/kg Streptozotocin. The thirty mice were allocated into six groups of five: Group 1 served as the normal control and received distilled water; Group 2 was the diabetic negative control, also receiving distilled water; Groups 3, 4 and 5 were diabetic mice treated with the plant leaf crude extracts at doses of 100, 200, and 400 mg/kg, respectively; and Group 6 was the diabetic standard control, treated with glibenclamide. On the first, 7th and 14th days, blood glucose levels were measured in the mouse`s tail. The in vitro antioxidant and alpha amylase inhibitory activities of the plant extracts were evaluated via 2,2-diphenyl-1-picrylhydrazyl scavenging and dinitrosalicylic acid assays, respectively. Data analysis was performed via one-way analysis of variance, followed by Tukey’s post hoc test, via the Statistical Package for Social Science software version 26.
resultsCompared with the negative control, Ocimum lamiifolium leaf hydromethanolic crude extract had a significant (p ≤ 0.05) antihyperglycaemic effect at all doses (100, 200 and 400 mg/kg) on the 7th and 14th days of treatment in diabetic mice. The groups treated with these doses also presented significant body weight gain during the same period. In vitro studies also revealed antioxidant effect and alpha amylase inhibitory effects comparable to those of the corresponding standard drugs, with half maximum inhibitory concentrations (IC50s) of 143.9 µg/ml and 127.53 µg/ml, respectively.
conclusionsThe results of this study indicate that Ocimum lamiifolium leaves significantly lowered blood glucose levels and improved body weight in mice with Streptozotocin-induced diabetes. These beneficial effects might be attributed to the plant extract`s antioxidant effect and its capacity to inhibit alpha-amylase, as shown by the phytochemical constituents found in the extract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.